BioCardia Inc Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

BioCardia Inc in the NEWS
BioCardia, Inc. (BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, today announced positive interim results from the Phase III randomized controlled trial of its CardiAMP® autologous cell therapy in 110 randomized patients with advanced chronic heart failure at a mean 20-month follow-up, (CardiAMP HF).

According to . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.